Evidence map›Paper›PMID 25444866›Full record

ArticlePharmacology, biochemistry, and behavior2015

The dopamine D1-D2 receptor heteromer exerts a tonic inhibitory effect on the expression of amphetamine-induced locomotor sensitization.

Maurice Y F Shen, Melissa L Perreault, Theresa Fan, Susan R George

Abstract read
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. G Protein-Coupled Receptor Dimerization-What Next?International journal of molecular sciences · 2024
    Review
  3. Daily ΔBiological psychiatry global open science · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Maurice Y F ShenCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Melissa L PerreaultCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Theresa FanCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Susan R GeorgeCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: s.george@utoronto.ca.
University of Toronto · CACentre for Addiction and Mental Health · CA

Funding

RECEPTORS MEDIATING DRUG DEPENDENCER01DA007223 · NIDA · UNIVERSITY OF TORONTO · PI GEORGE, SUSAN R · 1991 to 2013
$2.5M
NIDA NIH HHS DA-007223NIDA NIH HHS R01 DA007223
6 · The paper itself

Abstract

A role for the dopamine D1-D2 receptor heteromer in the regulation of reward and addiction-related processes has been previously implicated. In the present study, we examined the effects of D1-D2 heteromer stimulation by the agonist SKF 83959 and its disruption by a selective TAT-D1 peptide on amphetamine-induced locomotor sensitization, a behavioral model widely used to study the neuroadaptations associated with psychostimulant addiction. D1-D2 heteromer activation by SKF 83959 did not alter the acute locomotor effects of amphetamine but significantly inhibited amphetamine-induced locomotor responding across the 5day treatment regimen. In addition, a single injection of SKF 83959 was sufficient to abolish the expression of locomotor sensitization induced by a priming injection of amphetamine after a 72-hour withdrawal. Conversely, inhibition of D1-D2 heteromer activity by the TAT-D1 peptide enhanced subchronic amphetamine-induced locomotion and the expression of amphetamine locomotor sensitization. Treatment solely with the TAT-D1 disrupting peptide during the initial 5day treatment phase was sufficient to induce a sensitized locomotor phenotype in response to the priming injection of amphetamine. Together these findings demonstrate that the dopamine D1-D2 receptor heteromer exerts a tonic inhibitory control on neurobiological processes involved in sensitization to amphetamine, indicating that the dopamine D1-D2 receptor heteromer may be a novel molecular substrate in addiction processes involving psychostimulants.

Indexed as

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepineAmphetamineAmphetamine-Related DisordersAnimalsBehavior, AnimalCentral Nervous System StimulantsDopamine AntagonistsDopamine D2 Receptor AntagonistsMaleMotor ActivityMultiprotein ComplexesPeptide FragmentsRatsRats, Sprague-DawleyReceptors, Dopamine D1Receptors, Dopamine D22,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepineAmphetamineCentral Nervous System StimulantsDopamine AntagonistsDopamine D2 Receptor AntagonistsMultiprotein ComplexesPeptide FragmentsReceptors, Dopamine D1Receptors, Dopamine D2SK&F 83959AmphetamineDopamine D1–D2 receptor heteromerLocomotor sensitization

Identifiers

PMID25444866
PMCPMC4460003
OpenAlexW2031999765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.